



**RDT**<sup>TM</sup>

**RAPID DOSE THERAPEUTICS**

**BUSINESS OVERVIEW | DECEMBER 2018**

**CSE: DOSE**

# Disclaimer

This documentation is a presentation (the “Presentation”) of general background information about the current activities of Rapid Dose Therapeutics (RDT) Canada Inc. (“RDT”) as of December 13, 2018. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities and assessing the business of RDT are reminded that any such purchase must not be made on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding RDT.

**Cautionary Note Regarding Forward-Looking Statements:** Certain information in this document may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

# Recent news





# About Rapid Dose Therapeutics (RDT)

## Game Changing Delivery

Rapid Dose Therapeutics, RDT, is a Canadian med-tech company providing a Managed Strip Service Program which enables proprietary drug delivery technologies designed to improve patient and consumer outcomes.

RDT provides a turnkey service program for product innovation, production, and consultation to the pharmaceutical, nutraceutical and cannabis industries. For more information, visit: [rapid-dose.com](https://rapid-dose.com)

## Mission

To create novel, convenient, enhanced rapid delivery therapeutics to improve healthcare outcomes for patients.



# RDT verticals

RDT has three business divisions — delivering health and therapeutic applications.



## Over the Counter (OTC) Nutraceuticals

- OTC product portfolio (NPN, Health Canada approved)
- QuickStrip™ Energy (Caffeine)
- QuickStrip™ B12
- QuickStrip™ Sleep (Melatonin)
- Other OTC products in the pipeline: QuickStrip™ Nicotine, Pain, Allergy, Vitamins
- Primary OTC targets for RDT are the large CDN US retail chains selling high volume consumer oriented products



## Cannabis

- QuickStrip™ medical and recreational markets
- RDT licenses proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a **recurring revenue model**
- QuickStrip™ — The discreet, smoke-free choice for consumers



## Pharmaceutical

- Branded drug manufacturers seeking alternative delivery to expand or enhance products where rapid dosage or simplified delivery are important factors.
- Opportunity for branded products in mid-cycle, near patent expiry, or line extension.

# RDT global brand

## QuickStrip™

### Anytime, Anywhere™

QuickStrip™ precisely delivers active Ingredients using an orally dissolvable strip to deliver the therapeutic dose **directly into the blood stream.**

**Quick,  
Convenient,  
Precise, Discreet™**

RDT's proprietary delivery system and trademarked brand QuickStrip™ transforms how pharmaceutical, nutraceuticals and cannabis are consumed.



The  
Smoke-Free  
Choice  
for cannabis  
consumers



Nutraceutical line



**⚡ENERGY ✨ VITAMIN B12 SLEEP ⭐**

# Current business status



Rapid Dose Therapeutics Inc.  
**Approved to be listed on the CSE**



Rapid Dose Therapeutics signs an exclusive preferred global vendor agreement with Aphria



**Exclusive contract with equipment supplier** for the cannabis sector in Canada



Definitive contract signed with Chemesis for the **state of California**



Nine contracts currently being negotiated in the **USA, UK, EU, South America, Caribbean, Central America**



Definitive contract signed with Chemesis for the **territory of Puerto Rico**

# Current business status cont'd



**Top Ten New Product** awarded by **Grocery Innovation Canada (GIC)** for non-food category



**Four patents** pending in **US** and **Canada**



Fourteen **trademarks** filed in Canada and the USA



QuickStrip™ available for retail in hotel kiosks in Las Vegas for Nutraceuticals: Energy, B12 & Sleep








Expanding operations for a further **35,000 sq ft. production** for **bottling, edibles, and QuickStrip products**



**Ten patents** in process of being filed



# Research & development – clinical studies

 <p><b>Researching polymer thin film technology</b> for oil-based therapeutics delivery</p>	 <p><b>EEG &amp; behavioural study underway with UNLV</b> with QuickStrip™ delivery system</p>	<p><b>B12</b></p> <p><b>Clinical review of B12 for IBS</b> with major medical institution in Canada</p>
 <p><b>Clinical study delivering CBD with QuickStrip™ delivery system</b>, uptake and potency with major US university</p>	 <p><b>Development of methods for producing and purifying cannabinoids</b> using natural, sustainable ingredients for use in both recreational and medicinal applications.</p>	 <p><b>Clinical study for Cannabis related benefits underway with UNLV</b> with QuickStrip™ delivery system</p>

# RDT cannabis vertical



In the process of submitting the application for a cannabis processing and retail license in Canada



License will permit manufacturing of cannabis products



The licensed facility provides the ability to further R&D for **new cannabis medical and recreational product development**



Plans to open RDT retail store in Burlington, Ontario — high visibility with QEW access.

# Strategic alliances

RDT has partnered with large cannabis corporations to manufacture QuickStrip™ and distribute to the global cannabis markets. RDT continues to build and expand this network.



#### **Distribution reach**

- State of California
- Territory of Puerto Rico
- Chemesis is currently retailing exclusive products in Puerto Rico and actively engaging retail storefronts in the California market
- Opened multiple retail locations and currently expanding into other marketplaces



#### **Distribution reach**

- Canada-wide distribution
- Europe
- South America
- Caribbean
- Australia
- Strong brand portfolio of cannabis products to fit consumer needs

# Strategic partnerships



Aphria secured  
**\$5.4M**  
private placement  
with RDT  
**7.2M** shares  
at **\$0.75**

- Research & development
- Clinical studies
- Manufacturing
- Marketing & sales

- High-quality genetics
- Expert Personnel
- Best practices
- Registered patient network
- Marketing & sales
- Global distribution channels

RDT Brand

Aphria-QuickStrip product distribution



Definitive agreement  
signed with RDT for  
exclusive **preferred**  
**global rights in Canada**





# Strategic alliance



Established networks and **current retail operations underway in key markets in California and Puerto Rico.**

**QuickStrip™ is positioned for rapid growth with Chemesis** in the emerging US cannabis industry. Chemesis is a fully-compliant, fully licensed, first mover within California — and has established presence serving Puerto Rico from seed to sale.



# RDT anticipated global strategic alliances




# Corporate video



# Appendix



# Global market outlook



<sup>1</sup> Global Dietary Supplements Market Report, Zion Research

<sup>2</sup> Hemp Business Journal, Greenwave Research

<sup>3</sup> Report by Arcview Market Research and BDS Analytics

# Marketing

Broadcast and PR



Investment News/PR — North America and Europe



FINANCIAL POST

Social media



E-commerce  
(soon to market)



Combined marketing with business alliances





Rapid Dose Therapeutics Corp.  
1121 Walkers Line  
Burlington ON L7N 2G4  
P: 1 416.477.1052

[info@rapid-dose.com](mailto:info@rapid-dose.com)  
[rapid-dose.com](http://rapid-dose.com)

CSE: DOSE